Compare Novavax Inc (NVAX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Under Armour Inc Class A — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Novavax Inc and Under Armour Inc Class A are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Under Armour Inc Class A for 99 Days on average.
| NVAX | UAA | |
|---|---|---|
Market Cap | $1.82B | $2.07B |
Volume | 6,198,505 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.75 | $8.14 |
52-Week Low | $6.22 | $4.17 |
Typical Hold Time | 59 Days | 99 Days |
Enterprise Value | $1.39B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and ROE (-29.82%) despite beating Q2 2026 EPS estimates. Recent news highlights the company's brand transformation efforts amid softer demand, with management maintaining profitability outlook despite revenue cuts.
The stock presents a high-risk opportunity with analyst consensus pointing to 18.6% upside to the $5.79 price target. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures. The 27% buy rating suggests cautious optimism, but investors need clear evidence of sustainable margin improvement and revenue stabilization for meaningful upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
